Welcome to our dedicated page for Helius Med Technologies news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Med Technologies stock.
Helius Medical Technologies Inc (NASDAQ: HSDT) is a pioneering neurotechnology company focused on non-invasive therapies for neurological deficits. This page provides investors and healthcare professionals with essential updates on HSDT's progress, including regulatory milestones, clinical trial results, and strategic initiatives.
Discover the latest developments surrounding the Portable Neuromodulation Stimulator (PoNS), partnerships with medical institutions, and financial performance updates. Our curated news collection ensures you stay informed about HSDT's advancements in neuroplasticity-based treatments for conditions like multiple sclerosis and traumatic brain injury.
This resource aggregates official press releases, earnings reports, and market-related announcements. Key coverage areas: FDA regulatory updates, clinical study outcomes, executive leadership changes, and technology licensing agreements. Bookmark this page for streamlined access to material information impacting HSDT's position in the medical device sector.
Helius Medical Technologies (NASDAQ: HSDT) has announced positive results from its PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP), supporting an upcoming FDA submission for treating gait and balance deficits in chronic stroke patients.
The program included three clinical trials with 159 total patients across 10 clinical sites in the US and Canada. The double-blind randomized trial successfully met its primary endpoint, demonstrating statistically significant improvements in gait/balance deficits with active PoNS therapy. The studies showed minimal adverse events and good treatment tolerability.
The company plans to submit an FDA application in Q3 2025 under its current Breakthrough Device Designation, targeting a market of over 7 million stroke patients, of which approximately 80% experience balance and gait deficits.
Helius Medical Technologies (Nasdaq: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has achieved full compliance with Nasdaq's continued listing requirements. The company received formal confirmation on July 7, 2025 from the Nasdaq Hearings Panel regarding compliance with the equity requirement (Rule 5550(b)(1)).
This follows their earlier compliance confirmation with the minimum bid price requirement (Rule 5550(a)(2)) received on June 3, 2025. The company will be subject to a Mandatory Panel Monitor for one year following this notification.
Helius Medical Technologies (Nasdaq:HSDT) has announced a 1-for-50 reverse stock split of its Class A common stock, effective June 30, 2025. The split will reduce outstanding shares from approximately 33.8 million to 0.7 million, while maintaining the authorized share count at 150 million.
Trading on the split-adjusted basis will begin July 1, 2025, under the same symbol "HSDT" but with a new CUSIP number (42328V 876). The reverse split was approved by stockholders on May 23, 2025, authorizing a ratio range of 1-for-2 to 1-for-250, with the final 1-for-50 ratio determined by the Board of Directors.
Helius Medical Technologies (NASDAQ: HSDT) has secured reimbursement approval from United Healthcare for its Portable Neuromodulation Stimulator (PoNS®) Device, making it the second major healthcare provider after Anthem to offer coverage. The approved reimbursement amount totals $18,100, which includes patient co-payment and represents the adjusted list price for out-of-network status.
The PoNS Device is designed to improve balance and gait deficits while reducing fall risk. This development marks a significant milestone in Helius's strategy to expand patient access through commercial payor coverage and third-party reimbursement, particularly benefiting MS patients.